NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
1.60
Dollar change
+0.17
Percentage change
11.89
%
Index- P/E- EPS (ttm)-1.55 Insider Own54.36% Shs Outstand13.97M Perf Week3.90%
Market Cap22.36M Forward P/E- EPS next Y-1.51 Insider Trans0.30% Shs Float6.38M Perf Month-8.37%
Enterprise Value6.34M PEG- EPS next Q-0.35 Inst Own22.31% Short Float1.73% Perf Quarter-19.60%
Income-18.87M P/S- EPS this Y-26.02% Inst Trans105.11% Short Ratio4.09 Perf Half Y-43.96%
Sales0.00M P/B2.05 EPS next Y1.63% ROA-71.92% Short Interest0.11M Perf YTD-54.80%
Book/sh0.78 P/C0.91 EPS next 5Y-13.56% ROE-134.15% 52W High5.97 -73.20% Perf Year-65.67%
Cash/sh1.76 P/FCF- EPS past 3/5Y62.80% 47.54% ROIC-96.84% 52W Low1.43 11.89% Perf 3Y-87.01%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility13.09% 7.64% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM41.17% Oper. Margin- ATR (14)0.14 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.66 Sales Y/Y TTM- Profit Margin- RSI (14)45.69 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio5.66 EPS Q/Q-2867.44% SMA20-3.80% Beta1.18 Target Price16.00
Payout- Debt/Eq0.79 Sales Q/Q- SMA50-7.06% Rel Volume2.05 Prev Close1.43
Employees14 LT Debt/Eq0.79 EarningsMay 14 BMO SMA200-40.84% Avg Volume26.97K Price1.60
IPOSep 25, 2020 Option/ShortNo / Yes EPS/Sales Surpr.-17.38% - Trades Volume55,215 Change11.89%
Jun-25-25 07:00AM
Jun-12-25 07:00AM
May-14-25 07:00AM
Apr-17-25 07:00AM
Apr-02-25 12:00PM
07:00AM Loading…
Apr-01-25 07:00AM
Mar-27-25 07:00AM
Mar-05-25 07:00AM
Mar-04-25 07:00AM
Feb-19-25 07:00AM
Feb-03-25 04:05PM
Jan-14-25 07:00AM
Nov-21-24 08:00AM
Nov-20-24 04:05PM
Nov-13-24 07:00AM
07:00AM Loading…
Nov-07-24 07:00AM
Oct-30-24 10:11PM
04:50PM
07:00AM
Oct-28-24 04:05PM
Oct-16-24 08:00AM
Sep-03-24 08:00AM
Aug-12-24 04:10PM
Jul-09-24 07:30AM
Jul-08-24 08:00AM
Jul-01-24 08:00AM
Jun-27-24 08:00AM
07:06AM
Jun-26-24 04:05PM
May-28-24 07:53AM
09:48AM Loading…
May-21-24 09:48AM
May-13-24 04:05PM
May-07-24 08:00AM
Apr-24-24 08:00AM
Apr-10-24 03:30PM
Mar-28-24 11:53AM
07:00AM
Mar-13-24 08:00AM
Feb-28-24 06:57PM
Feb-13-24 08:00AM
Feb-07-24 04:05PM
Jan-22-24 08:00AM
Dec-11-23 07:30AM
Nov-09-23 07:00AM
Nov-02-23 09:15AM
Sep-06-23 07:30AM
Aug-31-23 07:30AM
Aug-11-23 07:01AM
Aug-10-23 04:05PM
06:24AM
Aug-09-23 07:30AM
06:26AM
Aug-08-23 06:28AM
Aug-07-23 06:35AM
Aug-04-23 07:14AM
Aug-03-23 07:15AM
Aug-02-23 07:52AM
Aug-01-23 06:51AM
Jul-31-23 06:44AM
Jul-28-23 07:58AM
Jul-27-23 07:10AM
Jul-26-23 01:12PM
Jul-25-23 07:16AM
Jul-24-23 07:12AM
Jul-21-23 07:23AM
Jul-20-23 06:55AM
Jul-19-23 07:10AM
Jul-18-23 06:53AM
Jul-17-23 07:10AM
Jul-14-23 06:50AM
Jul-13-23 07:02AM
Jul-12-23 07:22AM
Jul-11-23 06:08AM
Jul-10-23 06:56AM
Jul-05-23 06:46AM
Jul-03-23 06:50AM
Jun-30-23 06:52AM
Jun-29-23 06:49AM
Jun-28-23 06:58AM
Jun-27-23 06:46AM
Jun-26-23 06:41AM
Jun-23-23 09:24AM
Jun-12-23 07:30AM
Jun-06-23 07:30AM
May-23-23 07:30AM
May-15-23 08:55AM
Mar-29-23 07:53PM
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roberts Eric WCHIEF BUSINESS OFFICERJun 26 '25Buy1.444,5006,48332,823Jun 27 07:35 PM
Bardin StephenChief Financial OfficerJun 26 '25Buy1.502,0003,0053,000Jun 26 06:30 PM
Roberts Eric WCHIEF BUSINESS OFFICERJun 11 '25Buy1.855,0009,25028,323Jun 13 05:05 PM
Roberts Eric WCHIEF BUSINESS OFFICERJun 06 '25Buy1.775,0008,87523,323Jun 09 04:08 PM
Roberts Eric WCHIEF BUSINESS OFFICERJun 05 '25Buy1.705,1008,67018,323Jun 09 04:08 PM
Bardin StephenChief Financial OfficerMay 30 '25Buy1.691,0001,69041,000Jun 03 05:10 PM
MIDDLETON FRED ADirectorDec 06 '24Buy2.654,80012,72036,514Dec 06 07:12 PM
Sanderling Venture Partners VI10% OwnerNov 01 '24Buy3.7586,867325,751814,300Nov 05 03:08 PM
Sanderling Venture Partners VI10% OwnerNov 01 '24Buy3.758773,28922,479Nov 05 03:08 PM
MIDDLETON FRED ADirectorNov 01 '24Buy3.7587,744329,040814,300Nov 05 03:04 PM
MIDDLETON FRED ADirectorNov 01 '24Buy3.7520,00075,00031,714Nov 05 03:04 PM
Leheny A. RachelCHIEF EXECUTIVE OFFICERNov 01 '24Buy3.7520,00075,000130,926Nov 01 01:25 PM
Roberts Eric WCHIEF BUSINESS OFFICERNov 01 '24Buy3.7553,333199,999164,706Nov 01 01:24 PM
WILSON ROBERT NDirectorNov 01 '24Buy3.7553,333199,999417,529Nov 01 01:22 PM
Dunn Michael J.President and COOSep 09 '24Option Exercise1.3911,76116,34811,761Sep 11 05:00 PM
Leheny A. RachelCHIEF EXECUTIVE OFFICERAug 27 '24Buy4.191,0004,190110,926Aug 27 07:44 PM
Roberts Eric WCHIEF BUSINESS OFFICERAug 23 '24Buy3.575,00017,86746,894Aug 26 06:00 PM
WILSON ROBERT NDirectorAug 23 '24Buy3.7254,000200,826364,196Aug 26 05:57 PM
Roberts Eric WCHIEF BUSINESS OFFICERAug 21 '24Buy4.045,00020,20044,894Aug 22 06:02 PM